<table>
<thead>
<tr>
<th>EO/PA Status</th>
<th>EO Count</th>
<th>% EO Total</th>
<th>PA Count</th>
<th>% of PA Total</th>
<th>Total Count (Non-Tobacco)</th>
<th>% of Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>APPROVED</td>
<td>5287</td>
<td>77.56%</td>
<td>4545</td>
<td>52.35%</td>
<td>9832</td>
<td>63.44%</td>
</tr>
<tr>
<td>CALLTRACK</td>
<td>0</td>
<td>0.00%</td>
<td>78</td>
<td>0.90%</td>
<td>78</td>
<td>0.50%</td>
</tr>
<tr>
<td>CANCEL</td>
<td>0</td>
<td>0.00%</td>
<td>52</td>
<td>0.60%</td>
<td>52</td>
<td>0.34%</td>
</tr>
<tr>
<td>CLOSED</td>
<td>148</td>
<td>2.17%</td>
<td>155</td>
<td>1.79%</td>
<td>303</td>
<td>1.95%</td>
</tr>
<tr>
<td>DENIED</td>
<td>821</td>
<td>12.04%</td>
<td>2617</td>
<td>30.14%</td>
<td>3438</td>
<td>22.18%</td>
</tr>
<tr>
<td>INPROCESS</td>
<td>2</td>
<td>4.20%</td>
<td>75</td>
<td>0.86%</td>
<td>77</td>
<td>0.50%</td>
</tr>
<tr>
<td>MEDREVIEW</td>
<td>286</td>
<td>4.00%</td>
<td>516</td>
<td>5.94%</td>
<td>802</td>
<td>5.17%</td>
</tr>
<tr>
<td>PENDING</td>
<td>273</td>
<td>4.00%</td>
<td>644</td>
<td>7.42%</td>
<td>917</td>
<td>5.92%</td>
</tr>
<tr>
<td><strong>Total Program</strong></td>
<td><strong>6817</strong></td>
<td><strong>42.21%</strong></td>
<td><strong>8682</strong></td>
<td><strong>53.75%</strong></td>
<td><strong>15499</strong></td>
<td><strong>95.96%</strong></td>
</tr>
<tr>
<td># Member ID# s</td>
<td>6444</td>
<td>1.06</td>
<td>8459</td>
<td>1.03</td>
<td>14903</td>
<td>1.04</td>
</tr>
</tbody>
</table>

**Graphs:**
- **Graph 1:** EO Count, PA Count, Total Count (Non-Tobacco)
- **Graph 2:** Tobacco, Auto-PA
### October 2017 Program Summary

<table>
<thead>
<tr>
<th>EO/PA Status</th>
<th>EO Count</th>
<th>% EO Total</th>
<th>PA Count</th>
<th>% PA Total</th>
<th>Total Count</th>
<th>% of Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>APPROVED</td>
<td>6405</td>
<td>79.83%</td>
<td>5071</td>
<td>53.78%</td>
<td>11476</td>
<td>65.76%</td>
</tr>
<tr>
<td>CALLTRACK</td>
<td>0</td>
<td>0.00%</td>
<td>95</td>
<td>1.01%</td>
<td>95</td>
<td>0.54%</td>
</tr>
<tr>
<td>CANCEL</td>
<td>0</td>
<td>0.00%</td>
<td>62</td>
<td>0.66%</td>
<td>62</td>
<td>0.36%</td>
</tr>
<tr>
<td>CLOSED</td>
<td>266</td>
<td>3.32%</td>
<td>225</td>
<td>2.39%</td>
<td>491</td>
<td>2.81%</td>
</tr>
<tr>
<td>DENIED</td>
<td>757</td>
<td>9.44%</td>
<td>2756</td>
<td>29.23%</td>
<td>3513</td>
<td>20.13%</td>
</tr>
<tr>
<td>INPROCESS</td>
<td>6</td>
<td>3.23%</td>
<td>79</td>
<td>0.84%</td>
<td>85</td>
<td>0.49%</td>
</tr>
<tr>
<td>MEDREVIEW</td>
<td>259</td>
<td>4.11%</td>
<td>565</td>
<td>5.99%</td>
<td>824</td>
<td>4.72%</td>
</tr>
<tr>
<td>PENDING</td>
<td>330</td>
<td>4.11%</td>
<td>576</td>
<td>6.11%</td>
<td>906</td>
<td>5.19%</td>
</tr>
<tr>
<td><strong>Total Program</strong></td>
<td><strong>8023</strong></td>
<td><strong>44.00%</strong></td>
<td><strong>9429</strong></td>
<td><strong>51.71%</strong></td>
<td><strong>17452</strong></td>
<td><strong>95.70%</strong></td>
</tr>
</tbody>
</table>

![Graph showing EO Count, PA Count, and Total Count (Non-Tobacco)](image1)

![Graph showing Tobacco and Auto-PA](image2)
Volume Trend for June-Oct.

PA-EO Monthly Volume

- Yellow line: Edit Overrides
- Green line: Prior Auths
- Red line: Total

- June
- July
- Aug.
- Sept.
- Oct.
## September 2017 Edit Overrides (EO)

<table>
<thead>
<tr>
<th>EO Status</th>
<th>7069 Therapy Duplication</th>
<th>7073 Early Refill</th>
<th>7511 MEQ Exceeded</th>
<th>7155 MaxRxDays Limitation</th>
<th>7026 Disp &gt; Exceeds Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>APPROVED</td>
<td>80.07%</td>
<td>81.24%</td>
<td>85.23%</td>
<td>81.21%</td>
<td>57.10%</td>
</tr>
<tr>
<td>CLOSED</td>
<td>1.68%</td>
<td>2.70%</td>
<td>5.44%</td>
<td>0.29%</td>
<td>0.62%</td>
</tr>
<tr>
<td>DENIED</td>
<td>10.99%</td>
<td>11.82%</td>
<td>1.56%</td>
<td>6.65%</td>
<td>35.49%</td>
</tr>
<tr>
<td>INPROCESS</td>
<td>0.04%</td>
<td>0.00%</td>
<td>0.16%</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>MEDREVIEW</td>
<td>2.39%</td>
<td>2.48%</td>
<td>5.13%</td>
<td>2.60%</td>
<td>4.63%</td>
</tr>
<tr>
<td>PENDING</td>
<td>4.82%</td>
<td>1.75%</td>
<td>2.49%</td>
<td>9.25%</td>
<td>2.16%</td>
</tr>
<tr>
<td>Total EO's</td>
<td>2674</td>
<td>1370</td>
<td>643</td>
<td>346</td>
<td>324</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EO Status</th>
<th>7502 Missing/Invalid Prescriber Type</th>
<th>7071 Ingredient Duplication</th>
<th>7187 User Max Units limits</th>
<th>7196 Sum of Rx Qty Exceeds Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>APPROVED</td>
<td>92.63%</td>
<td>86.90%</td>
<td>71.70%</td>
<td>37.39%</td>
</tr>
<tr>
<td>CLOSED</td>
<td>4.21%</td>
<td>0.40%</td>
<td>1.42%</td>
<td>0.87%</td>
</tr>
<tr>
<td>DENIED</td>
<td>1.40%</td>
<td>6.75%</td>
<td>11.32%</td>
<td>44.35%</td>
</tr>
<tr>
<td>INPROCESS</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>MEDREVIEW</td>
<td>0.70%</td>
<td>0.40%</td>
<td>4.72%</td>
<td>11.30%</td>
</tr>
<tr>
<td>PENDING</td>
<td>1.05%</td>
<td>5.56%</td>
<td>10.85%</td>
<td>6.09%</td>
</tr>
<tr>
<td>Total EO's</td>
<td>285</td>
<td>252</td>
<td>212</td>
<td>115</td>
</tr>
</tbody>
</table>
## October 2017 Edit Overrides (EO)

<table>
<thead>
<tr>
<th>EO Status</th>
<th>7069 Therapeutic Duplication</th>
<th>7073 Early Refill</th>
<th>7511 MEQ Exceeded</th>
<th>7155 MaxRxDays Limitation</th>
<th>7026 Disp &gt; Exceeds Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>APPROVED</td>
<td>82.17%</td>
<td>82.35%</td>
<td>80.72%</td>
<td>90.53%</td>
<td>59.87%</td>
</tr>
<tr>
<td>CLOSED</td>
<td>1.66%</td>
<td>3.43%</td>
<td>11.91%</td>
<td>0.74%</td>
<td>1.25%</td>
</tr>
<tr>
<td>DENIED</td>
<td>9.19%</td>
<td>10.36%</td>
<td>1.26%</td>
<td>3.69%</td>
<td>28.84%</td>
</tr>
<tr>
<td>INPROCESS</td>
<td>0.04%</td>
<td>0.06%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>MEDREVIEW</td>
<td>1.52%</td>
<td>1.41%</td>
<td>3.90%</td>
<td>1.23%</td>
<td>3.76%</td>
</tr>
<tr>
<td>PENDING</td>
<td>5.42%</td>
<td>2.39%</td>
<td>2.21%</td>
<td>3.81%</td>
<td>6.27%</td>
</tr>
<tr>
<td>Total EO's</td>
<td>2765</td>
<td>1632</td>
<td>949</td>
<td>813</td>
<td>319</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EO Status</th>
<th>7071 Ingredient Duplication</th>
<th>7502 Missing/Invalid Prescriber Type</th>
<th>7187 User Max Units limits</th>
<th>7196 Sum of Rx Qnty Exceeds Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>APPROVED</td>
<td>92.75%</td>
<td>94.17%</td>
<td>76.69%</td>
<td>49.33%</td>
</tr>
<tr>
<td>CLOSED</td>
<td>1.81%</td>
<td>2.92%</td>
<td>3.81%</td>
<td>2.67%</td>
</tr>
<tr>
<td>DENIED</td>
<td>2.54%</td>
<td>1.25%</td>
<td>8.47%</td>
<td>37.33%</td>
</tr>
<tr>
<td>INPROCESS</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>MEDREVIEW</td>
<td>0.36%</td>
<td>0.42%</td>
<td>2.54%</td>
<td>5.33%</td>
</tr>
<tr>
<td>PENDING</td>
<td>2.54%</td>
<td>1.25%</td>
<td>8.47%</td>
<td>5.33%</td>
</tr>
<tr>
<td>Total EO's</td>
<td>276</td>
<td>240</td>
<td>236</td>
<td>150</td>
</tr>
</tbody>
</table>
October 2017 Edit Overrides (EO)
<table>
<thead>
<tr>
<th>HIC3</th>
<th>Definition</th>
<th>Count</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>J5B</td>
<td>ADRENERGICS, AROMATIC, NON-CATECHOLAMINE</td>
<td>333</td>
<td>12.45%</td>
</tr>
<tr>
<td>H2V</td>
<td>TX FOR ATTENTION DEFICIT-HYPERACT(ADHD)/NARCOLEPSY</td>
<td>280</td>
<td>10.47%</td>
</tr>
<tr>
<td>H3U</td>
<td>NARCOTIC ANALGESIC &amp; NON-SALICYLATE ANALGESIC COMB</td>
<td>253</td>
<td>9.46%</td>
</tr>
<tr>
<td>H3A</td>
<td>ANALGESICS, NARCOTICS</td>
<td>199</td>
<td>7.44%</td>
</tr>
<tr>
<td>S2B</td>
<td>NSAIDS, CYCLOOXYGENASE INHIBITOR TYPE</td>
<td>180</td>
<td>6.73%</td>
</tr>
<tr>
<td>H2F</td>
<td>ANTI-ANXIETY DRUGS</td>
<td>130</td>
<td>4.86%</td>
</tr>
<tr>
<td>H4B</td>
<td>ANTICONVULSANTS</td>
<td>126</td>
<td>4.71%</td>
</tr>
<tr>
<td>A4D</td>
<td>HYPOTENSIVES, ACE INHIBITORS</td>
<td>114</td>
<td>4.26%</td>
</tr>
<tr>
<td>D4J</td>
<td>PROTON-PUMP INHIBITORS</td>
<td>110</td>
<td>4.11%</td>
</tr>
<tr>
<td>H2E</td>
<td>SEDATIVE-HYPNOTICS, NON-BARBITURATE</td>
<td>80</td>
<td>2.99%</td>
</tr>
<tr>
<td>A4F</td>
<td>HYPOTENSIVES, ANGIOTENSIN RECEPTOR ANTAGONIST</td>
<td>77</td>
<td>2.88%</td>
</tr>
<tr>
<td>C4G</td>
<td>INSULINS</td>
<td>76</td>
<td>2.84%</td>
</tr>
<tr>
<td>H6H</td>
<td>SKELETAL MUSCLE RELAXANTS</td>
<td>74</td>
<td>2.77%</td>
</tr>
<tr>
<td>H7T</td>
<td>ANTIPSYCHOTICS, ATYPICAL, DOPAMINE, &amp; SEROTONIN ANTAG</td>
<td>68</td>
<td>2.54%</td>
</tr>
<tr>
<td>M4E</td>
<td>LIPOTROPICS</td>
<td>53</td>
<td>1.98%</td>
</tr>
</tbody>
</table>
## October Therapy Duplications by Class

<table>
<thead>
<tr>
<th>HIC3</th>
<th>Definition</th>
<th>Count</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>J5B</td>
<td>ADRENERGICS, AROMATIC, NON-CATECHOLAMINE</td>
<td>326</td>
<td>11.79%</td>
</tr>
<tr>
<td>H2V</td>
<td>TX FOR ATTENTION DEFICIT-HYPERACT(ADHD)/NARCOLEPSY</td>
<td>292</td>
<td>10.56%</td>
</tr>
<tr>
<td>H3U</td>
<td>NARCOTIC ANALGESIC &amp; NON-SALICYLATE ANALGESIC COMB</td>
<td>259</td>
<td>9.37%</td>
</tr>
<tr>
<td>H3A</td>
<td>ANALGESICS, NARCOTICS</td>
<td>179</td>
<td>6.47%</td>
</tr>
<tr>
<td>S2B</td>
<td>NSAIDS, CYCLOOXYGENASE INHIBITOR TYPE</td>
<td>171</td>
<td>6.18%</td>
</tr>
<tr>
<td>A4D</td>
<td>HYPOTENSIVES, ACE INHIBITORS</td>
<td>152</td>
<td>5.50%</td>
</tr>
<tr>
<td>H4B</td>
<td>ANTICONVULSANTS</td>
<td>147</td>
<td>5.32%</td>
</tr>
<tr>
<td>D4J</td>
<td>PROTON-PUMP INHIBITORS</td>
<td>144</td>
<td>5.21%</td>
</tr>
<tr>
<td>H2F</td>
<td>ANTI-ANXIETY DRUGS</td>
<td>121</td>
<td>4.38%</td>
</tr>
<tr>
<td>A4F</td>
<td>HYPOTENSIVES, ANGIOTENSIN RECEPTOR ANTAGOST</td>
<td>102</td>
<td>3.69%</td>
</tr>
<tr>
<td>H6H</td>
<td>SKELETAL MUSCLE RELAXANTS</td>
<td>88</td>
<td>3.18%</td>
</tr>
<tr>
<td>M4D</td>
<td>ANTIHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS</td>
<td>75</td>
<td>2.71%</td>
</tr>
<tr>
<td>H2E</td>
<td>SEDATIVE-HYPNOTICS, NON-BARBITURATE</td>
<td>74</td>
<td>2.68%</td>
</tr>
<tr>
<td>C4G</td>
<td>INSULINS</td>
<td>73</td>
<td>2.64%</td>
</tr>
<tr>
<td>H7T</td>
<td>ANTIPSYCHOTICS, ATYPICAL, DOPAMINE, &amp; SEROTONIN ANTAG</td>
<td>64</td>
<td>2.31%</td>
</tr>
<tr>
<td>GCN Seqno</td>
<td>Drug Name</td>
<td>Drug Strength</td>
<td>Count</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------------------------------</td>
<td>------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>021414</td>
<td>GABAPENTIN</td>
<td>300 MG</td>
<td>72</td>
</tr>
<tr>
<td>066636</td>
<td>BUPRENORPHINE HCL/NALOXONE HCL</td>
<td>8 MG-2 MG</td>
<td>55</td>
</tr>
<tr>
<td>006373</td>
<td>BLOOD SUGAR DIAGNOSTIC</td>
<td></td>
<td>42</td>
</tr>
<tr>
<td>062867</td>
<td>INSULIN GLARGINE,HUM.REC.ANLOG</td>
<td>100/ML (3)</td>
<td>35</td>
</tr>
<tr>
<td>046229</td>
<td>SERTRALINE HCL</td>
<td>100 MG</td>
<td>25</td>
</tr>
<tr>
<td>021415</td>
<td>GABAPENTIN</td>
<td>400 MG</td>
<td>24</td>
</tr>
<tr>
<td>028090</td>
<td>ALBUTEROL SULFATE</td>
<td>90 MCG</td>
<td>20</td>
</tr>
<tr>
<td>000346</td>
<td>CLONIDINE HCL</td>
<td>0.1 MG</td>
<td>17</td>
</tr>
<tr>
<td>044341</td>
<td>INSULIN ASPART</td>
<td>100/ML</td>
<td>16</td>
</tr>
<tr>
<td>017872</td>
<td>LAMOTRIGINE</td>
<td>25 MG</td>
<td>15</td>
</tr>
<tr>
<td>013318</td>
<td>METFORMIN HCL</td>
<td>500 MG</td>
<td>14</td>
</tr>
<tr>
<td>047430</td>
<td>HYDROCODONE/ACETAMINOPHEN</td>
<td>5 MG-325MG</td>
<td>13</td>
</tr>
<tr>
<td>050631</td>
<td>METOPROLOL TARTRATE</td>
<td>25 MG</td>
<td>12</td>
</tr>
<tr>
<td>057893</td>
<td>DULOXETINE HCL</td>
<td>60 MG</td>
<td>12</td>
</tr>
<tr>
<td>023139</td>
<td>TRAMADOL HCL</td>
<td>50 MG</td>
<td>12</td>
</tr>
<tr>
<td>027462</td>
<td>PANTOPRAZOLE SODIUM</td>
<td>40 MG</td>
<td>10</td>
</tr>
<tr>
<td>GCN Seqno</td>
<td>Drug Name</td>
<td>Drug Strength</td>
<td>Count</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------------</td>
<td>--------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>021414</td>
<td>GABAPENTIN</td>
<td>300 MG</td>
<td>76</td>
</tr>
<tr>
<td>066636</td>
<td>BUPRENORPHINE HCL/NALOXONE HCL</td>
<td>8 MG-2 MG</td>
<td>75</td>
</tr>
<tr>
<td>006373</td>
<td>BLOOD SUGAR DIAGNOSTIC</td>
<td></td>
<td>42</td>
</tr>
<tr>
<td>062867</td>
<td>INSULIN GLARGINE,HUM.REC.ANLOG</td>
<td>100/ML (3)</td>
<td>37</td>
</tr>
<tr>
<td>021415</td>
<td>GABAPENTIN</td>
<td>400 MG</td>
<td>35</td>
</tr>
<tr>
<td>000346</td>
<td>CLONIDINE HCL</td>
<td>0.1 MG</td>
<td>27</td>
</tr>
<tr>
<td>046229</td>
<td>SERTRALINE HCL</td>
<td>100 MG</td>
<td>25</td>
</tr>
<tr>
<td>028090</td>
<td>ALBUTEROL SULFATE</td>
<td>90 MCG</td>
<td>23</td>
</tr>
<tr>
<td>023139</td>
<td>TRAMADOL HCL</td>
<td>50 MG</td>
<td>22</td>
</tr>
<tr>
<td>027462</td>
<td>PANTOPRAZOLE SODIUM</td>
<td>40 MG</td>
<td>18</td>
</tr>
<tr>
<td>002169</td>
<td>ERGOCALCIFEROL (VITAMIN D2)</td>
<td>500000 UNIT</td>
<td>17</td>
</tr>
<tr>
<td>011672</td>
<td>RANITIDINE HCL</td>
<td>15 MG/ML</td>
<td>17</td>
</tr>
<tr>
<td>046241</td>
<td>TRAZODONE HCL</td>
<td>50 MG</td>
<td>16</td>
</tr>
<tr>
<td>070374</td>
<td>METHYLPHENIDATE HCL</td>
<td>5 MG/ML</td>
<td>13</td>
</tr>
<tr>
<td>003774</td>
<td>ALPRAZOLAM</td>
<td>0.5 MG</td>
<td>13</td>
</tr>
</tbody>
</table>
## September 2017 Prior Approvals

<table>
<thead>
<tr>
<th></th>
<th>Atypical Anti-psychotics</th>
<th>Amphetamines</th>
<th>Anti-convulsants</th>
<th>Narcotic Withdrawal Agents</th>
<th>GLP-1 RECEPTOR AGONIST</th>
<th>PROTON-PUMP INHIBITORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>APPROVED</td>
<td>67.19%</td>
<td>79.41%</td>
<td>64.94%</td>
<td>76.23%</td>
<td>37.00%</td>
<td>50.49%</td>
</tr>
<tr>
<td>CALLTRACK</td>
<td>0.61%</td>
<td>1.56%</td>
<td>0.26%</td>
<td>1.16%</td>
<td>0.00%</td>
<td>0.65%</td>
</tr>
<tr>
<td>CANCEL</td>
<td>0.12%</td>
<td>0.17%</td>
<td>0.00%</td>
<td>7.25%</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>CLOSED</td>
<td>4.25%</td>
<td>1.38%</td>
<td>1.04%</td>
<td>3.48%</td>
<td>1.83%</td>
<td>0.98%</td>
</tr>
<tr>
<td>DENIED</td>
<td>15.43%</td>
<td>8.82%</td>
<td>18.44%</td>
<td>8.12%</td>
<td>47.71%</td>
<td>36.16%</td>
</tr>
<tr>
<td>INPROCESS</td>
<td>0.49%</td>
<td>0.17%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.65%</td>
</tr>
<tr>
<td>MEDREVIEW</td>
<td>2.79%</td>
<td>4.84%</td>
<td>3.38%</td>
<td>1.45%</td>
<td>2.75%</td>
<td>5.86%</td>
</tr>
<tr>
<td>PENDING</td>
<td>9.11%</td>
<td>3.63%</td>
<td>11.95%</td>
<td>2.32%</td>
<td>10.70%</td>
<td>5.21%</td>
</tr>
<tr>
<td>Totals</td>
<td>823</td>
<td>578</td>
<td>385</td>
<td>345</td>
<td>327</td>
<td>307</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>ADD Agents</th>
<th>Direct Factor XA Inhibitors</th>
<th>SGLT-2 Inhibitors</th>
<th>Heparins</th>
<th>Insulins</th>
<th>Narcotic Analgesics</th>
</tr>
</thead>
<tbody>
<tr>
<td>APPROVED</td>
<td>60.07%</td>
<td>86.46%</td>
<td>36.07%</td>
<td>89.53%</td>
<td>33.15%</td>
<td>73.62%</td>
</tr>
<tr>
<td>CALLTRACK</td>
<td>0.99%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>CANCEL</td>
<td>2.31%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.61%</td>
</tr>
<tr>
<td>CLOSED</td>
<td>2.31%</td>
<td>2.62%</td>
<td>0.91%</td>
<td>2.09%</td>
<td>0.56%</td>
<td>6.75%</td>
</tr>
<tr>
<td>DENIED</td>
<td>18.15%</td>
<td>3.06%</td>
<td>46.58%</td>
<td>1.57%</td>
<td>51.69%</td>
<td>12.27%</td>
</tr>
<tr>
<td>INPROCESS</td>
<td>0.33%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>1.05%</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>MEDREVIEW</td>
<td>14.19%</td>
<td>0.44%</td>
<td>2.28%</td>
<td>0.00%</td>
<td>8.43%</td>
<td>5.52%</td>
</tr>
<tr>
<td>PENDING</td>
<td>1.65%</td>
<td>7.42%</td>
<td>14.16%</td>
<td>5.76%</td>
<td>6.18%</td>
<td>1.23%</td>
</tr>
<tr>
<td>Totals</td>
<td>303</td>
<td>229</td>
<td>219</td>
<td>191</td>
<td>178</td>
<td>163</td>
</tr>
</tbody>
</table>
September 2017 Prior Approvals Chart

- Atypical Anti-psychotics
- Amphetamines
- Anti-convulsants
- Narcotic Withdrawal Agents
- GLP-1 RECEPTOR AGONIST
- PROTON-PUMP INHIBITORS
- ADD Agents
- Direct Factor XA Inhibitors
- SGLT-2 Inhibitors
- Heparins
- Insulins
- Narcotic Analgesics

Legend:
- PENDING
- IN REVIEW
- IN PROCESS
- DENIED
- CLOSED
- CANCEL
- ON TRACK
- APPROVED
## October 2017 Prior Approvals

<table>
<thead>
<tr>
<th></th>
<th>Atypical Anti-psychotics</th>
<th>Amphetamines</th>
<th>Anti-convulsants</th>
<th>Atomoxetine (Strattera)</th>
<th>GLP-1 RECEPTOR AGONIST</th>
<th>ADD Agents</th>
<th>SGLT-2 Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>APPROVED</td>
<td>72.10%</td>
<td>77.64%</td>
<td>69.40%</td>
<td>74.56%</td>
<td>37.82%</td>
<td>53.80%</td>
<td>38.98%</td>
</tr>
<tr>
<td>CALLTRACK</td>
<td>0.56%</td>
<td>0.96%</td>
<td>0.72%</td>
<td>0.25%</td>
<td>0.56%</td>
<td>1.98%</td>
<td>0.00%</td>
</tr>
<tr>
<td>CANCEL</td>
<td>0.00%</td>
<td>0.32%</td>
<td>0.00%</td>
<td>0.25%</td>
<td>0.00%</td>
<td>0.33%</td>
<td>0.34%</td>
</tr>
<tr>
<td>CLOSED</td>
<td>5.58%</td>
<td>2.40%</td>
<td>1.69%</td>
<td>3.27%</td>
<td>0.28%</td>
<td>2.64%</td>
<td>1.02%</td>
</tr>
<tr>
<td>DENIED</td>
<td>12.83%</td>
<td>10.22%</td>
<td>15.90%</td>
<td>13.10%</td>
<td>50.70%</td>
<td>19.14%</td>
<td>49.83%</td>
</tr>
<tr>
<td>INPROCESS</td>
<td>0.78%</td>
<td>0.32%</td>
<td>0.24%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.34%</td>
</tr>
<tr>
<td>MEDREVIEW</td>
<td>2.57%</td>
<td>6.07%</td>
<td>5.30%</td>
<td>6.80%</td>
<td>1.12%</td>
<td>19.80%</td>
<td>1.02%</td>
</tr>
<tr>
<td>PENDING</td>
<td>5.58%</td>
<td>2.08%</td>
<td>6.75%</td>
<td>1.76%</td>
<td>9.52%</td>
<td>2.31%</td>
<td>8.47%</td>
</tr>
<tr>
<td>Totals</td>
<td>896</td>
<td>626</td>
<td>415</td>
<td>397</td>
<td>357</td>
<td>303</td>
<td>295</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Direct Factor XA Inhibitors</th>
<th>Narcotic Withdrawal Agents</th>
<th>Proton-Pump Inhibitors</th>
<th>Heparin Products</th>
<th>Narcotic Analgesics</th>
<th>Synagis</th>
<th>Insulins</th>
</tr>
</thead>
<tbody>
<tr>
<td>APPROVED</td>
<td>82.01%</td>
<td>72.20%</td>
<td>38.28%</td>
<td>83.85%</td>
<td>70.79%</td>
<td>44.89%</td>
<td>35.09%</td>
</tr>
<tr>
<td>CALLTRACK</td>
<td>0.36%</td>
<td>1.44%</td>
<td>0.78%</td>
<td>0.52%</td>
<td>1.69%</td>
<td>2.27%</td>
<td>2.34%</td>
</tr>
<tr>
<td>CANCEL</td>
<td>0.00%</td>
<td>12.64%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>CLOSED</td>
<td>3.96%</td>
<td>2.53%</td>
<td>0.00%</td>
<td>4.69%</td>
<td>9.55%</td>
<td>0.57%</td>
<td>2.92%</td>
</tr>
<tr>
<td>DENIED</td>
<td>3.60%</td>
<td>4.33%</td>
<td>50.39%</td>
<td>2.08%</td>
<td>8.99%</td>
<td>36.36%</td>
<td>42.69%</td>
</tr>
<tr>
<td>INPROCESS</td>
<td>0.72%</td>
<td>0.72%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.57%</td>
<td>0.00%</td>
</tr>
<tr>
<td>MEDREVIEW</td>
<td>1.44%</td>
<td>2.53%</td>
<td>4.69%</td>
<td>3.13%</td>
<td>6.74%</td>
<td>2.84%</td>
<td>7.02%</td>
</tr>
<tr>
<td>PENDING</td>
<td>7.91%</td>
<td>3.61%</td>
<td>5.86%</td>
<td>5.73%</td>
<td>2.25%</td>
<td>12.50%</td>
<td>9.94%</td>
</tr>
<tr>
<td>Totals</td>
<td>278</td>
<td>277</td>
<td>256</td>
<td>192</td>
<td>178</td>
<td>176</td>
<td>171</td>
</tr>
</tbody>
</table>
Issues

Any Questions?